Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.37 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5041750 | 0.86 | ADORA2A (0.44) | ADORA2AADORA1ADORA2BP2RX3P2RX2 | |
| SCHEMBL5044329 | 0.82 | KDM4E (0.43) | ADORA2AADORA1ADORA2BPIP4K2APIK3CG | |
| SCHEMBL6441873 | 0.77 | ADORA2A (0.53) | ADORA2AADORA1ADORA2BHPGDKDM4E | |
| SCHEMBL6441017 | 0.76 | ADORA2A (0.51) | ADORA2AADORA1ADORA2BHPGDSMN1; SMN2 | |
| SCHEMBL6442392 | 0.75 | ADORA2A (0.46) | ADORA2AADORA1ADORA2BHPGDKDM4E | |
| SCHEMBL5040419 | 0.75 | ADORA2A (0.48) | ADORA2AADORA1ADORA2BHPGDKDM4E | |
| SCHEMBL5040165 | 0.74 | ALDH1A1 (0.41) | ADORA2AADORA1ADORA2BHPGDKDM4E | |
| SCHEMBL6441055 | 0.74 | ADORA2A (0.52) | ADORA2AADORA1ADORA2BHPGDSMN1; SMN2 | |
| SCHEMBL6444797 | 0.71 | P2RX3 (0.40) | ADORA2AADORA1P2RX3P2RX2HPGD | |
| SCHEMBL6443503 | 0.71 | P2RX3 (0.38) | P2RX3P2RX2SMN1; SMN2KDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1525215-A1 | PROGESTERONE RECEPTOR MODULATORS HAVING AN INCREASED ANTIGONADOTROPIC ACTIVITY FOR USE IN FEMALE FERTILITY TESTING AND HORMONE REPLACEMENT THERAPY | Schering Aktiengesellschaft (DE) | 2005-04-27 | — | — | EP | claimed |
| WO-2004014935-A1 | PROGESTERONE RECEPTOR MODULATORS HAVING AN INCREASED ANTIGONADOTROPIC ACTIVITY FOR USE IN FEMALE FERTILITY TESTING AND HORMONE REPLACEMENT THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-02-19 | — | — | WO | claimed |
| EP-1525215-A1 | PROGESTERONE RECEPTOR MODULATORS HAVING AN INCREASED ANTIGONADOTROPIC ACTIVITY FOR USE IN FEMALE FERTILITY TESTING AND HORMONE REPLACEMENT THERAPY | Schering Aktiengesellschaft (DE) | 2005-04-27 | — | — | EP | disclosed |
| EP-1261327-B1 | ADENOSINE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004014935-A1 | PROGESTERONE RECEPTOR MODULATORS HAVING AN INCREASED ANTIGONADOTROPIC ACTIVITY FOR USE IN FEMALE FERTILITY TESTING AND HORMONE REPLACEMENT THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-02-19 | — | — | WO | disclosed |
| US-6586441-B2 | 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders | HOFFMAN-LA ROCHE INC. | 2003-07-01 | — | — | US | disclosed |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.